Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin-Reference-Cited by-同舟云学术

Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin

Published:2010-06-20 Issue:4 Volume:67 Page:829-835
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Ueda Yutaka,Miyake Takahito,Egawa-Takata Tomomi,Miyatake Takashi,Matsuzaki Shinya,Yokoyama Takuhei,Yoshino Kiyoshi,Fujita Masami,Enomoto Takayuki,Kimura Tadashi

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://www.springerlink.com/index/pdf/10.1007/s00280-010-1384-z

Reference24 articles.

1. DiSaia PJ, Creasman WT (2002) Clinical gynecologic oncology, 6th edn. St. Louis, Mosby

2. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ (2000) Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 78:85–91

3. Berek JS (2002) Novak’s Gynecology, 13th edn. William and Wilkins, Baltimore

4. Randall ME, Filiaci VL, Muss H, Spirtos NM, Mannel RS, Fowler J, Thigpen JT, Benda JA (2006) Gynecologic oncology group study randomized phase iii trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 24:36–44

5. Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R (2008) Japanese gynecologic oncology group randomized phase iii trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate—and high risk endometrial cancer: a Japanese gynecologic oncology group study. Gynecol Oncol 108:226–233

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer;Clinical Therapeutics;2023-10

2. Understanding Characteristics, Treatment Patterns, and Clinical Outcomes for Individuals with Advanced or Recurrent Endometrial Cancer in Alberta, Canada: A Retrospective, Population-Based Cohort Study;Current Oncology;2023-02-14

3. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer;Gynecologic Oncology;2022-12

4. Reassessment of intensive surveillance practices adopted for endometrial cancer survivors;BMC Women's Health;2022-08-23

5. Previously treated recurrent or advanced endometrial cancer in England: A real-world observational analysis;Gynecologic Oncology;2022-08